Extrapulmonary Small Cell Carcinoma
📧 Sign up to get email alerts when something new happens for Extrapulmonary Small Cell Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-12-02Clinical Trial Update: Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC [Phase 2]
Phase 2 clinical trial assessing CDK4/6 inhibitors for chemo-refractory, RB wild-type extensive small-cell lung cancer. The study also inclu…
-
CLINICAL_TRIALS research · 2025-02-10Clinical Trial Update: Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS) [Phase 2]
TAURUS is a Phase 2 clinical trial evaluating tarlatamab for advanced extrapulmonary small cell carcinoma and neuroendocrine carcinoma, with…
-
CLINICAL_TRIALS research · 2024-06-18Clinical Trial Update: AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA [Phase 2]
A Phase II single-arm trial evaluating durvalumab in combination with platinum-etoposide chemotherapy as first-line treatment for extensive-…
-
CLINICAL_TRIALS trial_result · 2022-04-12Clinical Trial Update: Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers [Phase 1, Phase 2]
A Phase 1/2 trial update reports completed results for combining topotecan with the ATR inhibitor berzosertib (VX-970/M6620) in small cell c…